SCYX-7158 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
65原発性免疫不全症候群2

65. 原発性免疫不全症候群


臨床試験数 : 500 薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03087955
(ClinicalTrials.gov)
October 11, 20167/3/2017Prospective Study on Efficacy and Safety of Acoziborole (SCYX-7158) in Patients Infected by Human African Trypanosomiasis Due to T.b. GambienseEfficacy and Safety Study of Acoziborole (SCYX-7158) in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Gambiense: a Multicentre, Open-label, Prospective StudyTrypanosomiasis, African;Gambiense Trypanosomiasis;Sleeping SicknessDrug: Acoziborole (SCYX-7158)Drugs for Neglected DiseasesNULLCompleted15 YearsN/AAll260Phase 2/Phase 3Congo, The Democratic Republic of the;Guinea
2NCT01533961
(ClinicalTrials.gov)
February 201213/2/2012Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158Randomized, Double-blind, Placebo-controlled Sequential Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SCYX-7158 After Single Oral Ascending Doses in Healthy Male VolunteersTrypanosomiasis;Trypanosomiasis, African;Protozoan Infections;Parasitic DiseasesDrug: SCYX-7158;Drug: PlaceboDrugs for Neglected DiseasesNULLCompleted18 Years45 YearsMale136Phase 1France